Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation

• Published in: Nature communications Vol. 11; no. 1; pp. 3360 - 15
• Main Authors: Barbier-Torres, Lucía, Fortner, Karen A., Iruzubieta, Paula, Delgado, Teresa C., Giddings, Emily, Chen, Youdinghuan, Champagne, Devin, Fernández-Ramos, David, Mestre, Daniela, Gomez-Santos, Beatriz, Varela-Rey, Marta, de Juan, Virginia Gutiérrez, Fernández-Tussy, Pablo, Zubiete-Franco, Imanol, García-Monzón, Carmelo, González-Rodríguez, Águeda, Oza, Dhaval, Valença-Pereira, Felipe, Fang, Qian, Crespo, Javier, Aspichueta, Patricia, Tremblay, Frederic, Christensen, Brock C., Anguita, Juan, Martínez-Chantar, María Luz, Rincón, Mercedes
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 03.07.2020; Nature Publishing Group; Nature Portfolio
• Subjects: 13/51; 13/89; 13/95; 14/19; 14/34; 14/63; 38/22; 38/77; 38/88; 631/154/51/2053; 64/110; 692/4020/4021/1607/2750; Adult; Aged; Animal models; Animals; Damage accumulation; Datasets as Topic; Degeneration; Diet, High-Fat - adverse effects; Disease Models, Animal; Drug development; Electron transport chain; Fatty acids; Fatty Acids - metabolism; Fatty liver; Female; Fibrosis; Hepatocytes; Hepatocytes - cytology; Hepatocytes - drug effects; Hepatocytes - metabolism; HSP40 Heat-Shock Proteins - antagonists & inhibitors; HSP40 Heat-Shock Proteins - genetics; HSP40 Heat-Shock Proteins - metabolism; Humanities and Social Sciences; Humans; J protein; Lipids; Liver; Liver - cytology; Liver - drug effects; Liver - pathology; Liver diseases; Male; Methylation; Middle Aged; Mitochondria; Mitochondria - drug effects; Mitochondria - metabolism; Mitochondrial Proteins - antagonists & inhibitors; Mitochondrial Proteins - genetics; Mitochondrial Proteins - metabolism; Molecular Chaperones - antagonists & inhibitors; Molecular Chaperones - genetics; Molecular Chaperones - metabolism; multidisciplinary; Nanoparticles; Nanoparticles - administration & dosage; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic Fatty Liver Disease - etiology; Non-alcoholic Fatty Liver Disease - pathology; Oxidation; Oxidation-Reduction - drug effects; Primary Cell Culture; RNA, Small Interfering - administration & dosage; RNA-Seq; Science; Science (multidisciplinary); siRNA; Therapeutic targets

Nonalcoholic fatty liver disease (NAFLD) is considered the next major health epidemic with an estimated 25% worldwide prevalence. No drugs have yet been approved and NAFLD remains a major unmet need. Here, we identify MCJ (Methylation-Controlled J protein) as a target for non-alcoholic steatohepatit...